...
search icon
tnxp-img

Tonix Pharmaceuticals Holding Corp, Common Stock

TNXP

NAQ

$18.04

+$0.03

(0.17%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$117.06M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
515.33K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.51
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.76 L
$672 H
$18.04

About Tonix Pharmaceuticals Holding Corp, Common Stock

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTNXPSectorS&P500
1-Week Return5.24%-0.55%1.46%
1-Month Return3.67%-4.67%-1.17%
3-Month Return-7.18%-7.33%-7.27%
6-Month Return29.86%-7.51%-2.9%
1-Year Return-96.81%-2.8%10.83%
3-Year Return-99.98%5.53%33.76%
5-Year Return-100%39.67%96.19%
10-Year Return-100%88%163.98%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue---7.77M10.09M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":76.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue50.51M92.31M112.09M4.74M7.76M[{"date":"2020-12-31","value":45.06,"profit":true},{"date":"2021-12-31","value":82.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.23,"profit":true},{"date":"2024-12-31","value":6.93,"profit":true}]
Gross Profit(50.51M)(92.31M)(112.09M)3.03M2.33M[{"date":"2020-12-31","value":-1668.68,"profit":false},{"date":"2021-12-31","value":-3049.62,"profit":false},{"date":"2022-12-31","value":-3703.04,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":76.94,"profit":true}]
Gross Margin---38.97%23.07%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":59.21,"profit":true}]
Operating Expenses50.51M92.31M112.09M121.41M139.03M[{"date":"2020-12-31","value":36.33,"profit":true},{"date":"2021-12-31","value":66.4,"profit":true},{"date":"2022-12-31","value":80.62,"profit":true},{"date":"2023-12-31","value":87.32,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(50.51M)(92.31M)(112.09M)(118.38M)(136.70M)[{"date":"2020-12-31","value":-5051100000,"profit":false},{"date":"2021-12-31","value":-9231200000,"profit":false},{"date":"2022-12-31","value":-11209100000,"profit":false},{"date":"2023-12-31","value":-11838000000,"profit":false},{"date":"2024-12-31","value":-13670100000,"profit":false}]
Total Non-Operating Income/Expense96.00K50.00K3.75M4.49M-[{"date":"2020-12-31","value":2.14,"profit":true},{"date":"2021-12-31","value":1.11,"profit":true},{"date":"2022-12-31","value":83.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(50.46M)(92.29M)(110.22M)(116.66M)(130.04M)[{"date":"2020-12-31","value":-5046300000,"profit":false},{"date":"2021-12-31","value":-9228700000,"profit":false},{"date":"2022-12-31","value":-11021800000,"profit":false},{"date":"2023-12-31","value":-11665800000,"profit":false},{"date":"2024-12-31","value":-13003600000,"profit":false}]
Income Taxes(75.00K)(75.00K)4.79M(1.00)-[{"date":"2020-12-31","value":-1.57,"profit":false},{"date":"2021-12-31","value":-1.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(50.39M)(92.21M)(115.00M)(116.66M)-[{"date":"2020-12-31","value":-5038800000,"profit":false},{"date":"2021-12-31","value":-9221200000,"profit":false},{"date":"2022-12-31","value":-11500400000,"profit":false},{"date":"2023-12-31","value":-11665799900,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(50.46M)(92.29M)(110.22M)(121.02M)(130.04M)[{"date":"2020-12-31","value":-5046300000,"profit":false},{"date":"2021-12-31","value":-9228700000,"profit":false},{"date":"2022-12-31","value":-11021800000,"profit":false},{"date":"2023-12-31","value":-12101600000,"profit":false},{"date":"2024-12-31","value":-13003600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(50.39M)(92.21M)(115.00M)(116.66M)(130.04M)[{"date":"2020-12-31","value":-5038800000,"profit":false},{"date":"2021-12-31","value":-9221200000,"profit":false},{"date":"2022-12-31","value":-11500400000,"profit":false},{"date":"2023-12-31","value":-11665800000,"profit":false},{"date":"2024-12-31","value":-13003600000,"profit":false}]
EPS (Diluted)(23.04)(8.32)(4.07)(8.62)(29.46)[{"date":"2020-12-31","value":-2304,"profit":false},{"date":"2021-12-31","value":-832,"profit":false},{"date":"2022-12-31","value":-407,"profit":false},{"date":"2023-12-31","value":-862,"profit":false},{"date":"2024-12-31","value":-2945.58,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TNXP
Cash Ratio 5.40
Current Ratio 6.50
Quick Ratio 6.04

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TNXP
ROA (LTM) -30.62%
ROE (LTM) -106.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TNXP
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TNXP
Trailing PE NM
Forward PE NM
P/S (TTM) 12.27
P/B 0.86
Price/FCF NM
EV/R 2.87
EV/Ebitda 0.94
PEG NM

FAQs

What is Tonix Pharmaceuticals Holding Corp share price today?

Tonix Pharmaceuticals Holding Corp (TNXP) share price today is $18.04

Can Indians buy Tonix Pharmaceuticals Holding Corp shares?

Yes, Indians can buy shares of Tonix Pharmaceuticals Holding Corp (TNXP) on Vested. To buy Tonix Pharmaceuticals Holding Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TNXP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Tonix Pharmaceuticals Holding Corp be purchased?

Yes, you can purchase fractional shares of Tonix Pharmaceuticals Holding Corp (TNXP) via the Vested app. You can start investing in Tonix Pharmaceuticals Holding Corp (TNXP) with a minimum investment of $1.

How to invest in Tonix Pharmaceuticals Holding Corp shares from India?

You can invest in shares of Tonix Pharmaceuticals Holding Corp (TNXP) via Vested in three simple steps:

  • Click on Sign Up or Invest in TNXP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Tonix Pharmaceuticals Holding Corp shares
What is Tonix Pharmaceuticals Holding Corp 52-week high and low stock price?

The 52-week high price of Tonix Pharmaceuticals Holding Corp (TNXP) is $672. The 52-week low price of Tonix Pharmaceuticals Holding Corp (TNXP) is $6.76.

What is Tonix Pharmaceuticals Holding Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Tonix Pharmaceuticals Holding Corp (TNXP) is 0.86

What is the Market Cap of Tonix Pharmaceuticals Holding Corp?

The market capitalization of Tonix Pharmaceuticals Holding Corp (TNXP) is $117.06M

What is Tonix Pharmaceuticals Holding Corp’s stock symbol?

The stock symbol (or ticker) of Tonix Pharmaceuticals Holding Corp is TNXP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top